It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
DNA double-strand breaks are repaired by multiple pathways, including non-homologous end-joining (NHEJ) and microhomology-mediated end-joining (MMEJ). The balance of these pathways is dependent on the local chromatin context, but the underlying mechanisms are poorly understood. By combining knockout screening with a dual MMEJ:NHEJ reporter inserted in 19 different chromatin environments, we identified dozens of DNA repair proteins that modulate pathway balance dependent on the local chromatin state. Proteins that favor NHEJ mostly synergize with euchromatin, while proteins that favor MMEJ generally synergize with distinct types of heterochromatin. Examples of the former are BRCA2 and POLL, and of the latter the FANC complex and ATM. Moreover, in a diversity of human cancer types, loss of several of these proteins alters the distribution of pathway-specific mutations between heterochromatin and euchromatin. Together, these results uncover a complex network of proteins that regulate MMEJ:NHEJ balance in a chromatin context-dependent manner.
DNA double-strand breaks are repaired by multiple pathways. The balance of these pathways depends on the local chromatin context, but the underlying mechanisms are poorly understood. Here the authors uncover a network of proteins that regulate pathway balance in a chromatin context-dependent manner.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Manjón, Anna G. 2 ; de Haas, Marcel 3 ; Morris, Ben 4 ; Schep, Ruben 5 ; Leemans, Christ 5 ; Friskes, Anoek 2
; Beijersbergen, Roderick L. 6
; Sanders, Mathijs A. 7 ; Medema, René H. 2
; van Steensel, Bas 8
1 Netherlands Cancer Institute, Division of Gene Regulation, Amsterdam, The Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393); Netherlands Cancer Institute, Division of Molecular Genetics, Amsterdam, The Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393); Netherlands Cancer Institute, Division of Cell Biology, Amsterdam, The Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393); Oncode Institute, Utrecht, The Netherlands (GRID:grid.499559.d)
2 Netherlands Cancer Institute, Division of Cell Biology, Amsterdam, The Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393); Oncode Institute, Utrecht, The Netherlands (GRID:grid.499559.d)
3 Netherlands Cancer Institute, Division of Gene Regulation, Amsterdam, The Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393); Netherlands Cancer Institute, Division of Molecular Genetics, Amsterdam, The Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393); Oncode Institute, Utrecht, The Netherlands (GRID:grid.499559.d)
4 Netherlands Cancer Institute, NKI Robotics and Screening Center, Amsterdam, The Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393)
5 Netherlands Cancer Institute, Division of Gene Regulation, Amsterdam, The Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393); Oncode Institute, Utrecht, The Netherlands (GRID:grid.499559.d)
6 Netherlands Cancer Institute, NKI Robotics and Screening Center, Amsterdam, The Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393); Netherlands Cancer Institute, Division of Molecular Carcinogenesis, Amsterdam, The Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393)
7 Erasmus MC Cancer Institute, Department of Hematology, Rotterdam, The Netherlands (GRID:grid.508717.c) (ISNI:0000 0004 0637 3764); Wellcome Sanger Institute, Cancer, Ageing and Somatic Mutation (CASM), Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382)
8 Netherlands Cancer Institute, Division of Gene Regulation, Amsterdam, The Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393); Netherlands Cancer Institute, Division of Molecular Genetics, Amsterdam, The Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393); Oncode Institute, Utrecht, The Netherlands (GRID:grid.499559.d); Erasmus University Medical Center, Department of Cell Biology, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X)




